Company Filing History:
3 out of 9 
1 out of 1 
1 out of 255 
Years Active: 2001-2012
Title: Laura M Bartle: Innovator in Cancer Treatment
Introduction
Laura M Bartle is a prominent inventor based in Arlington, MA, known for her significant contributions to the field of cancer treatment. With a total of five patents to her name, she has made remarkable strides in developing innovative therapies targeting CD38 protein, which is crucial in various cancers and autoimmune diseases.
Latest Patents
Her latest patents include groundbreaking work on anti-CD38 antibodies designed for the treatment of cancer. These antibodies, including humanized and resurfaced variants, are capable of inducing apoptosis in CD38-expressing cells. They also facilitate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The applications of these antibodies extend to treating tumors such as multiple myeloma and chronic lymphocytic leukemia, as well as autoimmune diseases like systemic lupus and rheumatoid arthritis. Additionally, her patents cover cytotoxic conjugates that combine cell binding agents with cytotoxic agents, enhancing the efficacy of cancer treatments.
Career Highlights
Throughout her career, Laura has worked with notable companies such as Apoptosis Technology, Inc. and Sanofi Aventis. Her expertise in the field of apoptosis and anti-apoptotic gene products has positioned her as a leader in developing therapeutic compositions that regulate cell growth and stability.
Collaborations
Laura has collaborated with esteemed colleagues, including Anna Skaletskaya and Viktor S Goldmakher, contributing to her innovative research and development efforts.
Conclusion
Laura M Bartle's work exemplifies the intersection of innovation and healthcare, particularly in the fight against cancer. Her patents and collaborations reflect her commitment to advancing medical science and improving patient outcomes.